Olaratumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | PDGF-R α |
| Clinical data | |
| Trade names | Lartruvo |
| AHFS/Drugs.com | Monograph |
| Routes of administration |
Intravenous infusion |
| ATC code |
|
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Protein binding | None |
| Metabolism | Proteolytic enzymes |
| Biological half-life | 11 days |
| Identifiers | |
| Synonyms | IMC-3G3, LY-3012207 |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6554H10076N1736O2048S40 |
| Molar mass | 147.2 kg/mol |
  (what is this?)
|
|
Olaratumab (trade name Lartruvo) is a monoclonal antibody developed by Eli Lilly and Company for the treatment of solid tumors. It is directed against the platelet-derived growth factor receptor alpha.
Olaratumab is used in combination with doxorubicin for the treatment of adults with advanced soft-tissue sarcoma (STS) who cannot be cured by cancer surgery or radiation therapy, and who have not been previously treated with doxorubicin.
In a randomised controlled trial with 133 STS patients, olaratumab plus doxorubicin improved the median of progression-free survival from 4.1 to 6.6 months as compared to doxorubicin alone (p = 0.0615, narrowly missing statistical significance), and overall survival from 14.7 to 26.5 months (p = 0.0003, highly significant).
The drug has no contraindications apart from hypersensitivity reactions.
In studies, the most serious side effects of the combination olaratumab/doxorubicin were neutropenia (low count of neutrophil white blood cells) with a severity of grade 3 or 4 in 55% of patients, and musculoskeletal pain grade 3 or 4 in 8% of patients. Common milder side effects were lymphopenia, headache, diarrhoea, nausea and vomiting, mucositis, and reactions at the infusion site; all typical effects of cancer therapies.
No pharmacokinetic interactions with doxorubicin were observed in studies. Being a monoclonal antibody, olaratumab is neither metabolised by liver enzymes nor transported by transmembrane pumps, and is thus not expected to interact relevantly with other drugs.
...
Wikipedia